Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-label, Randomized, Three-period, Six-sequence Crossover Study in Healthy Adult Subjects to Evaluate the Bioavailability of an Oral Suspension Formulation Relative to the Tablet Formulation of Apremilast and to Assess the Effect of Food on the Pharmacokinetics of the Oral Suspension Formulation

Next Previous
Trial Profile

A Phase 1, Open-label, Randomized, Three-period, Six-sequence Crossover Study in Healthy Adult Subjects to Evaluate the Bioavailability of an Oral Suspension Formulation Relative to the Tablet Formulation of Apremilast and to Assess the Effect of Food on the Pharmacokinetics of the Oral Suspension Formulation

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 Aug 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apremilast (Primary)
  • Indications Plaque psoriasis
  • Focus Pharmacokinetics
  • Sponsors Amgen; Celgene Corporation

    • Most Recent Events

    • 25 Mar 2016 Planned number of patients changed from 36 to 34 as reported by ClinicalTrials.gov.
    • 25 Mar 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Feb 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top